Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthrough Treatment
Datroway metastatic breast cancer treatment has gained Priority Review from the US Food and Drug Administration (FDA) for first-line use in adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) ineligible for PD-1/PD-L1 inhibitors. This milestone for AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), builds on the TROPION-Breast02 Phase III trial results, as detailed in the AstraZeneca press release.
Trial Outcomes Fueling Regulatory Push
The core TROPION-Breast02 outcomes driving momentum: statistically significant improvements over chemotherapy, including a 5.0-month median overall survival (OS) benefit (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.64-0.98; p=0.0291) and a 43% reduction in disease progression or death risk (progression-free survival [PFS] HR 0.57; 95% CI 0.47-0.69; p<0.0001). If approved by Q2 2026 under the Prescription Drug User Fee Act, Datroway metastatic breast cancer therapy could become the standard of care for ~70% of patients currently limited to chemotherapy.
Efficacy Edge in Immunotherapy-Excluded Patients
Datroway metastatic breast cancer showed superior objective response rate (ORR) of 62.5% and median duration of response (DoR) of 12.3 months versus 29.3% and 7.1 months for chemotherapy. These gains matter for patients lacking PD-L1 expression, with prior immunotherapy, comorbidities, or access issues—including those with stable brain metastases. Safety mirrors prior breast cancer studies, positioning Datroway as a tolerable shift from chemotherapy, the only approved first-line option despite TNBC’s grim prognosis (median OS 12-18 months; 15% five-year survival).
Global Trial Rigor and TNBC Context
TROPION-Breast02 enrolled 644 patients across Africa, Asia, Europe, North America, and South America in a randomized, open-label design, pitting Datroway against chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin). It met dual primary endpoints of PFS (blinded independent central review) and OS, with secondary endpoints like ORR and DoR; data were unveiled at the 2025 ESMO Congress. TNBC represents 15% of breast cancers (~345,000 global cases yearly), hitting younger premenopausal Black and Hispanic women hardest, with TROP2 tied to progression. The sBLA leverages Project Orbis for faster global review.
HEOR Shifts and Market Implications
Datroway’s OS/PFS benefits could reshape health economics in metastatic breast cancer, supporting premium pricing and reimbursement under Inflation Reduction Act or ICER frameworks via lower resource use. Priority Review underscores FDA validation, easing payer talks for first-line status amid rising US TNBC cases (32,000-48,000 in 2025). It boosts ADC momentum (one of six Daiichi Sankyo DXd ADCs in AstraZeneca’s pipeline) and collaborative global efforts, paving the way for real-world evidence and equitable access.
